{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:52:51Z","timestamp":1782939171473,"version":"3.54.5"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Cancer Society"},{"name":"Mrs Berta Kamprad Foundation"},{"name":"Gustav V:s Jubilee Foundation, and governmental funding (ALF)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186284","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T13:41:05Z","timestamp":1508420465000},"page":"e0186284","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0051-8507","authenticated-orcid":true,"given":"Sofi","family":"Isaksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Monsef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r-Ola","family":"Bendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Staaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Planck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"issue":"2","key":"ref1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"LA Torre","year":"2015","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"22","key":"ref2","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1002\/cncr.24625","article-title":"Local recurrence after surgery for early stage lung cancer","volume":"115","author":"CR Kelsey","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"ref3","first-page":"163","article-title":"Diagnostic relevance of circulating biomarkers in patients with lung cancer","volume":"6","author":"R Molina","year":"2009","journal-title":"Cancer Biomarkers"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-3-26","article-title":"Follow-up of patients with curatively resected colorectal cancer: a practice guideline","volume":"3","author":"A Figueredo","year":"2003","journal-title":"BMC Cancer"},{"issue":"5","key":"ref5","first-page":"382","article-title":"Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum\/plasma markers","volume":"2","author":"PAJ Crosbie","year":"2013","journal-title":"Translational Lung Cancer Research"},{"issue":"11","key":"ref6","first-page":"937","article-title":"Diagnosis and Management of Ovarian Cancer","volume":"93","author":"CA Doubeni","year":"2016","journal-title":"American family physician"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines from the European Group on Tumor Markers (EGTM)","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cllc.2011.03.019","article-title":"Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non\u2013Small-Cell Lung Cancer (NSCLC)","volume":"12","author":"S Cedr\u00e9s","year":"2011","journal-title":"Clinical Lung Cancer"},{"issue":"4","key":"ref9","first-page":"3427","article-title":"Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer","volume":"23","author":"MJ Gaspar","year":"2003","journal-title":"Anticancer Res"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"MT Galgano","year":"2006","journal-title":"Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cca.2016.02.002","article-title":"Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer","volume":"455","author":"Q Zeng","year":"2016","journal-title":"Clinica Chimica Acta"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","article-title":"Serum HE4 as a diagnostic and prognostic marker for lung cancer","volume":"33","author":"K Iwahori","year":"2012","journal-title":"Tumor Biol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"e0128836","DOI":"10.1371\/journal.pone.0128836","article-title":"Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer","volume":"10","author":"P-J Lamy","year":"2015","journal-title":"PloS one"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbcan.2013.06.002","article-title":"Serum markers in small cell lung cancer: Opportunities for improvement","volume":"1836","author":"M Harmsma","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"11145","DOI":"10.3390\/ijms140611145","article-title":"Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients","volume":"14","author":"D Yu","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref16","article-title":"Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations","author":"KJ Suh","journal-title":"Clinical Lung Cancer"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3892\/mco.2015.568","article-title":"Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib","volume":"3","author":"M Inomata","year":"2015","journal-title":"Molecular and Clinical Oncology"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","article-title":"Systematic review of carbohydrate antigen (CA 19\u20139) as a biochemical marker in the diagnosis of pancreatic cancer","volume":"33","author":"KS Goonetilleke","year":"2007","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"issue":"1","key":"ref19","first-page":"24","article-title":"Diagnostic Role of Tumour Markers CEA, CA15-3, CA19-9 and CA125 in Lung Cancer. Indian journal of clinical biochemistry","volume":"28","author":"I Ghosh","year":"2013","journal-title":"IJCB"},{"issue":"3","key":"ref20","first-page":"155","article-title":"The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited","volume":"10","author":"S Ma","year":"2011","journal-title":"Cancer Biomarkers"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1309\/AJCP50RDXSCSBTBO","article-title":"Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study","volume":"140","author":"H Brunnstr\u00f6m","year":"2013","journal-title":"American journal of clinical pathology"},{"key":"ref22","article-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"BE Travis WD","year":"2004"},{"key":"ref23","article-title":"TNM classification of malignant tumours","author":"L GM Sobin","year":"2009"},{"issue":"21","key":"ref24","doi-asserted-by":"crossref","first-page":"34796","DOI":"10.18632\/oncotarget.16276","article-title":"Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer","volume":"8","author":"KE Lindquist","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ijc.11472","article-title":"Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer","volume":"107","author":"M Poll\u00e1n","year":"2003","journal-title":"International Journal of Cancer"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0169-5002(02)00009-0","article-title":"Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer","volume":"36","author":"N Reinmuth","year":"2002","journal-title":"Lung Cancer"},{"key":"ref27","unstructured":"Landstingens och regionernas nationella samverkansgrupp inom cancersjukv\u00e5rden. Lungcancer \u00c5rsrapport fr\u00e5n nationella lungcancerregistret (NCLCR). 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/lunga-ochlungsack\/kvalitetsregister\/rapport\/nlcr_tapport_tom2015_korr170111.pdf\" xlink:type=\"simple\">http:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/lunga-ochlungsack\/kvalitetsregister\/rapport\/nlcr_tapport_tom2015_korr170111.pdf<\/ext-link>."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T18:11:46Z","timestamp":1570212706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186284"}},"subtitle":[],"editor":[{"given":"William B.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186284","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}